ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas



Status:Recruiting
Conditions:Cancer, Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/28/2017
Start Date:October 2014
End Date:July 2018
Contact:Marie Payton
Email:mpayton@aileronrx.com

Use our guide to learn which trials are right for you!

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid
tumors or lymphomas with WT TP53.

Open label, multi-center dose escalation (DEP) and dose expansion (EXP) study designed to
evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor
effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-type (WT)
TP53. ALRN-6924 is a stapled peptide designed to disrupt integration between the p53 tumor
suppression protein and inhibition by murine double minute 2 (MDM2) and murine double minute
X (MDMX).

The DEP portion of the study will enroll adults with histologically- or
cytologically-confirmed malignancies that are metastatic or unresectable and for which
standard treatment(s) are not available or are no longer effective can be enrolled.The EXP
portion of the study will enroll distinct groups of patients with specific solid tumors
and/or lymphomas to further investigate the clinical safety profile and potential efficacy
of ALRN 6924 at the MTD or OBD. PTCL has been selected as one of the EXP groups to be
further studied.

Treatment of patients in the DEP and EXP phases will continue in the study until
documentation of disease progression, unacceptable toxicity, or patient or physician
decision to discontinue study participation is made.

Inclusion Criteria

- Male or female patients age 18 years and older, inclusive, at the time of informed
consent

- Histologically- or cytologically-confirmed malignancy that is metastatic or
unresectable and for which standard measures do not exist or are no longer effective
(DEP) or a histologically confirmed diagnosis of PTCL based on pathology review at
the local institution, using the most recent edition of the WHO Classification,
relapsed or refractory disease after at least one prior systemic anticancer regimen
(EXP in PTCL)

- WT TP53 status

- At least one target lesion that is measurable by RECIST 1.1 for solid tumors, or IWG
2014 for lymphoma

- ECOG (Eastern Cooperative Oncology Group) performance status 0-1

- Adequate hematologic function

- Adequate hepatic function

- Acceptable coagulation profile

- Recovery from significant toxicities from previous therapies and sufficient time
since last dose of previous therapy

Exclusion Criteria:

- Previous treatment with investigational agents that inhibit MDM2 or MDMX activity
(some MDM2-treated patients may be eligible)

- Known hypersensitivity to any study drug component

- Known and untreated brain metastases. Patients with primary CNS (central nervous
system) malignancies are excluded.

- History of coagulopathy, platelet disorder or history of non-drug induced
thrombocytopenia

- History of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or
untreated DVT (deep vein thrombosis)

- Required concurrent use of anti-coagulants or anti-platelet medication, with the
exception of aspirin doses ≤81 mg/day, low-dose SC heparin or SC low-molecular-weight
heparin for DVT prophylaxis, or heparin flushes to maintain IV catheter patency

- Patients with pre-existing history of or known cardiovascular risk

- Clinically significant gastrointestinal bleeding within 6 months prior to the first
dose of ALRN-6924

- Clinically significant third-space fluid accumulation

- Active uncontrolled infection, including HIV/AIDS or Hepatitis B or C

- Patients with cancers likely to be Human Papilloma Virus (HPV)-positive such as
cervical cancers, oropharyngeal cancers or anal cancers must undergo additional
screening to determine eligibility

- Known history of another primary malignancy that has not been in remission for ≥2
years

- Required use of medications predominantly cleared by hepatobiliary transporters
within 48 hours of study drug infusion
We found this trial at
12
sites
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-5638
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Phone: 206-288-6787
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Denver, Colorado 80218
Phone: 720-754-2610
?
mi
from
Denver, CO
Click here to add this to my saved trials
Duarte, California 91010
Phone: 626-218-9165
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Greenville, South Carolina 29605
Phone: 864-455-3600
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-563-2690
?
mi
from
Houston, TX
Click here to add this to my saved trials
Nashville, Tennessee 37203
Phone: 615-524-4455
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Sarasota, Florida 34232
Phone: 941-377-9993
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Tampa, Florida 33612
Phone: 813-745-4725
?
mi
from
Tampa, FL
Click here to add this to my saved trials
111 East 210th Street
The Bronx, New York 10467
Phone: 718-405-8515
?
mi
from
The Bronx, NY
Click here to add this to my saved trials